Insider · CIK 0001665124

Nagendran Sukumar

Reports to the SEC for 4 companies · DALLAS, TX

sec.gov

Transactions

Companies

Filings

CIK

0001665124

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-10	TSHATaysha Gene Therapies, Inc.S Sale	Director, President and Head of R&D	SSale	−200K sh	$6.24	−$1.25M	936,410
2026-06-10	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+77.5K sh	—	—	77,500
2026-04-10	TSHATaysha Gene Therapies, Inc.M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	+19K sh	$1.71	+$32.5K	1,336,410
2026-04-10	TSHATaysha Gene Therapies, Inc.S Sale	Director, President and Head of R&D	SSale	−200K sh	$4.46	−$892K	1,136,410
2026-04-10	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	−19K sh	—	—	455,920
2026-01-26	TSHATaysha Gene Therapies, Inc.S Sale	Director, President and Head of R&D	SSale	−26.9K sh	$4.61	−$124K	1,317,389
2026-01-23	TSHATaysha Gene Therapies, Inc.S Sale	Director, President and Head of R&D	SSale	−89.1K sh	$4.75	−$423K	1,344,307
2026-01-12	TSHATaysha Gene Therapies, Inc.M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	+111K sh	$0.70	+$77.8K	1,117,763
2026-01-12	TSHATaysha Gene Therapies, Inc.M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	+88.7K sh	$1.71	+$152K	1,206,439
2026-01-12	TSHATaysha Gene Therapies, Inc.S Sale	Director, President and Head of R&D	SSale	−200K sh	$4.71	−$942K	1,006,439
2026-01-12	TSHATaysha Gene Therapies, Inc.A Award	Director, President and Head of R&D	AAward	+427K sh	—	—	1,433,439
2026-01-12	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	−111K sh	—	—	111,359
2026-01-12	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	−88.7K sh	—	—	474,941
2026-01-12	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)A Award	Director, President and Head of R&D	AAward	+274K sh	—	—	274,000
2025-12-01	TSHATaysha Gene Therapies, Inc.M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	+260K sh	$1.71	+$445K	1,266,486
2025-12-01	TSHATaysha Gene Therapies, Inc.S Sale	Director, President and Head of R&D	SSale	−260K sh	$4.51	−$1.17M	1,006,439
2025-12-01	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	−260K sh	—	—	563,617
2025-11-28	TSHATaysha Gene Therapies, Inc.M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	+70.2K sh	$0.70	+$49K	1,076,611
2025-11-28	TSHATaysha Gene Therapies, Inc.M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	+40K sh	$1.71	+$68.3K	1,116,564
2025-11-28	TSHATaysha Gene Therapies, Inc.S Sale	Director, President and Head of R&D	SSale	−110K sh	$4.75	−$523K	1,006,439
2025-11-28	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	−70.2K sh	—	—	222,683
2025-11-28	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	−40K sh	—	—	823,664
2025-09-10	TSHATaysha Gene Therapies, Inc.M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	+41.2K sh	$0.70	+$28.8K	1,206,439
2025-09-10	TSHATaysha Gene Therapies, Inc.S Sale	Director, President and Head of R&D	SSale	−200K sh	$3.23	−$646K	1,006,439
2025-09-10	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Director, President and Head of R&D	MExercise/Conversion	−41.2K sh	—	—	292,855
2025-08-21	TSHATaysha Gene Therapies, Inc.S Sale	Director, President and Head of R&D	SSale	−57.1K sh	$2.85	−$163K	1,165,289
2025-06-12	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+77.5K sh	—	—	77,500
2025-01-02	TSHATaysha Gene Therapies, Inc.A Award	Director, President and Head of R&D	AAward	+325K sh	—	—	1,222,343
2025-01-02	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)A Award	Director, President and Head of R&D	AAward	+325K sh	—	—	324,500
2024-06-11	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+34.4K sh	—	—	34,400
2024-01-02	TSHATaysha Gene Therapies, Inc.A Award	Director, President and Head of R&D	AAward	+864K sh	—	—	897,843
2024-01-02	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)A Award	Director, President and Head of R&D	AAward	+864K sh	—	—	863,617
2023-12-14	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)A Award	Director, President and Head of R&D	AAward	+334K sh	—	—	334,005
2023-06-06	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+9,650 sh	—	—	9,650
2023-05-16	TSHATaysha Gene Therapies, Inc.P Purchase	Director, President and Head of R&D	PPurchase	+5,000 sh	$0.68	+$3,400	34,226
2022-12-30	TSHATaysha Gene Therapies, Inc. · Stock Option (right to buy)A Award	Director, President and Head of R&D	AAward	+790K sh	—	—	790,093
2022-12-13	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+9,650 sh	—	—	9,650
2022-06-17	TSHATaysha Gene Therapies, Inc. · Stock Option (right to buy)A Award	Director, President and Head of R&D	AAward	+15.5K sh	—	—	15,500
2022-06-07	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+51K sh	—	—	51,000
2022-02-02	TSHATaysha Gene Therapies, Inc.P Purchase	Director, President and Head of R&D	PPurchase	+10K sh	$8.01	+$80.1K	29,226
2021-06-17	TSHATaysha Gene Therapies, Inc. · Stock Option (right to buy)A Award	Director, President and Head of R&D	AAward	+15.5K sh	—	—	15,500
2021-06-16	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2020-09-28	TSHATaysha Gene Therapies, Inc.C Conversion	Director, President and Head of R&D	CConversion	+19.2K sh	—	—	19,226
2020-09-28	TSHATaysha Gene Therapies, Inc. · Series B Preferred StockC Conversion	Director, President and Head of R&D	CConversion	−17.6K sh	—	—	0
2020-09-23	TSHATaysha Gene Therapies, Inc. · Stock Option (right to buy)A Award	Director, President and Head of R&D	AAward	+31K sh	—	—	31,000
2020-06-16	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2020-06-16	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2019-07-25	SLDBSolid Biosciences Inc.A Award	Director	AAward	+32.3K sh	$4.65	+$150K	34,258
2019-06-13	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2018-12-13	SLDBSolid Biosciences Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+17.2K sh	—	—	17,240

Recent filings

Accepted (ET)
Jul 104
Nagendran Sukumar0001665124-26-000013
SEC(opens sec.gov)
Jun 114
Nagendran Sukumar0001193125-26-267504
SEC(opens sec.gov)
Apr 134
Nagendran Sukumar0001665124-26-000011
SEC(opens sec.gov)
Jan 274
Nagendran Sukumar0001665124-26-000008
SEC(opens sec.gov)
Jan 144
Nagendran Sukumar0001665124-26-000002
SEC(opens sec.gov)
Dec 14
Nagendran Sukumar0001665124-25-000003
SEC(opens sec.gov)

Companies

Address

C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430

DALLAS, TX, 75247